These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3839584)

  • 1. Elimination kinetics of amsacrine in the rabbit: evidence of nonlinearity.
    Paxton JW; Jurlina JL
    Pharmacology; 1985; 31(1):50-6. PubMed ID: 3839584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
    Paxton JW; Jurlina JL
    Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.
    Jurlina JL; Varcoe AR; Paxton JW
    Cancer Chemother Pharmacol; 1985; 14(1):21-5. PubMed ID: 3855288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The binding of amsacrine to human plasma proteins.
    Paxton JW; Jurlina JL; Foote SE
    J Pharm Pharmacol; 1986 Jun; 38(6):432-8. PubMed ID: 2873219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
    Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC
    Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.
    Paxton JW; Evans PC; Singh RM
    Cancer Chemother Pharmacol; 1987; 20(1):13-5. PubMed ID: 3621447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).
    Hall SW; Friedman J; Legha SS; Benjamin RS; Gutterman JU; Loo TL
    Cancer Res; 1983 Jul; 43(7):3422-6. PubMed ID: 6687834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of buthionine sulphoximine, cimetidine and phenobarbitone on the disposition of amsacrine in the rabbit.
    Paxton JW; Foote SE; Singh RM
    Cancer Chemother Pharmacol; 1986; 18(3):208-12. PubMed ID: 3802376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
    Paxton JW; Kim SN; Whitfield LR
    Cancer Res; 1990 May; 50(9):2692-7. PubMed ID: 2328494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.
    Paxton JW; Evans PC; Hardy JR
    Cancer Chemother Pharmacol; 1989; 23(5):291-5. PubMed ID: 2706733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of anticancer drugs in children.
    Evans WE; Crom WR; Sinkule JA; Yee GC; Stewart CF; Hutson PR
    Drug Metab Rev; 1983; 14(5):847-86. PubMed ID: 6197269
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
    Paxton JW
    J Pharm Pharmacol; 1986 Nov; 38(11):837-40. PubMed ID: 2879015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of amsacrine, an investigational antineoplastic agent.
    Grove WR; Fortner CL; Wiernik PH
    Clin Pharm; 1982; 1(4):320-6. PubMed ID: 6764391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
    Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC
    Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic and equilibrium studies of the interaction of amsacrine and anilino ring-substituted analogues with DNA.
    Denny WA; Wakelin LP
    Cancer Res; 1986 Apr; 46(4 Pt 1):1717-21. PubMed ID: 3753896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse.
    Paxton JW; Young D; Evans SM; Kestell P; Robertson IG; Cornford EM
    Cancer Chemother Pharmacol; 1992; 29(5):379-84. PubMed ID: 1551177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
    Paxton JW; Hardy JR; Evans PC; Harvey VJ; Baguley BC
    Cancer Chemother Pharmacol; 1988; 22(3):235-40. PubMed ID: 3409457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of amsacrine (m-AMSA), a new aminoacridine antitumor drug, on the rabbit heart.
    D'Alessandro N; Gebbia N; Crescimanno M; Flandina C; Leto G; Tumminello FM; Messina L
    Cancer Treat Rep; 1983 May; 67(5):467-74. PubMed ID: 6687838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption of m-AMSA and its biliary metabolites from the rat small intestine.
    Gormley PE; Shoemaker D; Rozencweig M; Ayers OC; Cysyk RL
    Eur J Cancer Clin Oncol; 1981 Oct; 17(10):1143-6. PubMed ID: 6896029
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
    Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 2000; 45(5):417-22. PubMed ID: 10803926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.